Psychedelics and the neurobiology of meaningfulness

Krystal and colleagues frame a tension in psychedelic research between two mechanistic accounts of therapeutic benefit: one emphasises direct neurobiological effects such as enhanced neuroplasticity and synaptogenesis, while the other emphasises the subjective, often profound, experiences users report—particularly a heightened sense of meaningfulness or portentousness. They note that some compounds that lack prominent hallucinatory effects nevertheless produce similar neuroplastic and antidepressant-like changes, which raises the possibility that subjective phenomenology may be irrelevant to therapeutic action. At the same time, many people rate psychedelic experiences among the most important of their lives, and earlier work shows that the degree to which an experience is judged as meaningful or important predicts clinical outcomes across conditions such as depression and addiction. The paper therefore asks whether the capacity of psychedelics to induce a feeling that something important is happening is itself a primary effect that might synergise with circuit- and plasticity-level processes to produce clinical benefit. The authors outline psychological mechanisms by which increased salience or a restored sense of purpose could promote adaptive learning and resilience, and they note that therapeutic insights reported after psychedelic sessions may sometimes reflect therapist-provided frames rather than intrinsic truths revealed by the drug experience. This sets up the central question of the commentary: are experiences of meaningfulness a cause, a correlate, or a consequence of therapeutic change following psychedelic administration?

The authors acknowledge a limited understanding of the neurobiology that gives rise to psychedelic-induced meaningfulness and propose several, non-exclusive hypotheses. Pharmacologically, meaningfulness appears to be 5-HT2A receptor dependent: ketanserin, a 5-HT2A antagonist, substantially attenuated LSD-induced attribution of relevance to previously meaningless stimuli in experimental work. Functional imaging in that context implicated multiple regions, including the supplementary motor area, dorsal anterior cingulate cortex, middle and superior frontal gyri, and posterior cingulate cortex, though the precise neural substrate remains difficult to define. Krystal and colleagues suggest three broad mechanistic possibilities. First, 5-HT2A activation might directly increase the salience of external stimuli, causing otherwise mundane inputs to be experienced as important. Second, psychedelics may reactivate salient autobiographical information, increasing personally referential meaning. Third, altered population dynamics under psychedelics or ketamine may create novel neural representations and prediction errors that render experience unexpectedly informative. The authors emphasise that induction of meaningfulness is tightly confounded with contemporaneous circuit-level changes that enhance synaptic plasticity; thus, meaningfulness may sometimes be a marker of adequate engagement of therapeutic targets (for example, 5-HT2A receptor activation) rather than an independent causal mechanism. They discuss ketamine as an instructive comparison: although dissociative and perceptual effects are salient to some, dissociation correlates with clinical improvement only in a subset of depressed patients, and increasing dissociative intensity by raising dose (from 0.5 mg/kg to 1.0 mg/kg) does not clearly increase efficacy. Preliminary pharmacology suggests it may be possible to develop compounds that produce antidepressant effects without strong subjective feelings of meaningfulness, yet the subjective dimension may still augment therapeutic response. The commentary cites an illustrative case in which a patient recovered following a psilocybin combination that produced no overt psychedelic effects but reported disappointment in the absence of a meaningful subjective experience. Finally, the authors note that meaningful experiences may foster resilience in non-clinical populations, but emphasise that current evidence does not establish whether meaningfulness is causally necessary, a by-product, or merely correlated with beneficial outcomes. They call for deeper investigation into the neural mechanisms that underlie how psychedelics generate meaningfulness and how those mechanisms relate to clinical benefit.